<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115953">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01832168</url>
  </required_header>
  <id_info>
    <org_study_id>AFRALP001</org_study_id>
    <nct_id>NCT01832168</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial Using Amniotic Membrane in Robotic Assisted Laparoscopic Prostatectomy</brief_title>
  <official_title>A Prospective Randomized Clinical Trial Using Amniotic Membrane in Robotic Assisted Laparoscopic Prostatectomy (RALP)- Effect on Nerve Protection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MiMedx Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MiMedx Group, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the AmnioFix dehydrated human amniotic
      membrane is effective in protecting nerves in men receiving robotic assisted laparoscopic
      prostatectomies.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of patients achieving return to baseline Sexual Health Inventory for Men (SHIM) score in the AmnioFix group versus the Control group.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to return of erectile function.</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores.</measure>
    <time_frame>10 days, 4 weeks, 3 months, and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Pudendal Nerve</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Robotic Assisted Laparoscopic Prostatectomy with application of absorbable hemostat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AmnioFix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Robotic Assisted Laparoscopic Prostatectomy with application of dehydrated human amniotic membrane.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Robotic Assisted Laparoscopic Prostatectomy</intervention_name>
    <description>Robotic Assisted Laparoscopic Prostatectomy with nerve-sparing technique</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>AmnioFix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Application of Absorbable Hemostat</intervention_name>
    <description>Application of Surgicel® SNoW Absorbable Hemostat by Johnson and Johnson on the neurovascular bundle after removal of the cancerous prostate.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Surgicel® SNoW</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Application of dehydrated human amniotic membrane</intervention_name>
    <description>Application of dehydrated human amniotic membrane (DHAM) on the neurovascular bundle after removal of the cancerous prostate.</description>
    <arm_group_label>AmnioFix</arm_group_label>
    <other_name>AmnioFix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages 45-70

          2. Clinically localized prostate cancer with Gleason score 6 or 7

          3. SHIM Score greater than or equal to 16 in the absence of medication

          4. Feasibility to perform unilateral or bilateral nerve sparing RALP

        Exclusion Criteria:

          1. Clinically locally advanced cancer and/or with Gleason score 8 or 9.

          2. Difficulty performing nerve sparing RALP.

          3. Prior surgery at the site.

          4. Site exhibits clinical signs and symptoms of infection.

          5. SHIM score at screening &lt;16.

          6. Current use of anticoagulant medication including Coumadin, Plavix, etc.

          7. Has had &quot;salvage prostatectomy&quot; - patients who failed prior therapies including
             external radiation therapy, cryotherapy, etc.

          8. Has prior radiation therapy treatment at the site.

          9. Prior hormonal therapy such as Lupron or oral anti-androgens.

         10. Non-mobile, i.e. not ambulatory or bed ridden.

         11. The presence of comorbidities that can be confused with or can exacerbate the
             condition including:

               1. diabetes

               2. advanced atherosclerotic vascular disease

         12. Patients with a history of more than two weeks treatment with immuno-suppressants
             (including systemic corticosteroids), cytotoxic chemotherapy within one month prior
             to initial screening, or who receive such medications during the screening period, or
             who are anticipated to require such medications during the course of the study.

         13. Patients on any investigational drug(s) or therapeutic device(s) within 30 days
             preceding screening.

         14. Unable to comply with penile rehabilitation.

         15. Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV.

         16. Patients who are unable to understand the aims and objectives of the trial.

         17. Presence of any condition(s) which seriously compromises the subject's ability to
             complete this study, or has a known history of poor adherence with medical treatment.

         18. Currently taking medications which could affect graft incorporation (supervising
             physician's discretion).

         19. Allergic to gentamicin and/or streptomycin.

         20. Damage to neurovascular bundles during surgery.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Razdan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jackson South Urology Center of Excellence</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jackson South Urology Center of Excellence</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>April 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
